Skip to main content

Advertisement

SpringerLink
Log in

Dysregulated glycolysis as an oncogenic event

  • Review
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Abstract

Enhanced glycolysis in cancer, called the Warburg effect, is a well-known feature of cancer metabolism. Recent advances revealed that the Warburg effect is coupled to many other cancer properties, including adaptation to hypoxia and low nutrients, immortalisation, resistance to oxidative stress and apoptotic stimuli, and elevated biomass synthesis. These linkages are mediated by various oncogenic molecules and signals, such as c-Myc, p53, and the insulin/Ras pathway. Furthermore, several regulators of glycolysis have been recently identified as oncogene candidates, including the hypoxia-inducible factor pathway, sirtuins, adenosine monophosphate-activated kinase, glycolytic pyruvate kinase M2, phosphoglycerate mutase, and oncometabolites. The interplay between glycolysis and oncogenic events will be the focus of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tarui S (1995) Glycolytic defects in muscle: aspects of collaboration between basic science and clinical medicine. Muscle Nerve Suppl 3:S2–S9. doi:10.1002/mus.880181404

    CAS  PubMed  Google Scholar 

  2. Bouche C, Serdy S, Kahn CR, Goldfine AB (2004) The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25(5):807–830. doi:10.1210/er.2003-0026

    CAS  PubMed  Google Scholar 

  3. Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269–270

    CAS  PubMed  Google Scholar 

  4. Durany N, Joseph J, Campo E, Molina R, Carreras J (1997) Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer 75(7):969–977

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84(6):1014–1020. doi:10.1016/j.ygeno.2004.08.010

    CAS  PubMed  Google Scholar 

  6. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033. doi:10.1126/science.1160809

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656–670. doi:10.1016/j.cell.2012.01.058

    PubMed Central  CAS  PubMed  Google Scholar 

  8. Hitosugi T, Zhou L, Elf S, Fan J, Kang HB, Seo JH, Shan C, Dai Q, Zhang L, Xie J, Gu TL, Jin P, Aleckovic M, Leroy G, Kang Y, Sudderth JA, Deberardinis RJ, Luan CH, Chen GZ, Muller S, Shin DM, Owonikoko TK, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Ye K, Boggon TJ, Kang S, He C, Chen J (2012) Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22(5):585–600. doi:10.1016/j.ccr.2012.09.020

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D (2005) Glycolytic enzymes can modulate cellular life span. Cancer Res 65(1):177–185

    CAS  PubMed  Google Scholar 

  10. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013

    CAS  PubMed  Google Scholar 

  11. Gitenay D, Wiel C, Lallet-Daher H, Vindrieux D, Aubert S, Payen L, Simonnet H, Bernard D (2014) Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. Cell Death Dis 5:e1089. doi:10.1038/cddis.2014.63

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Onodera Y, Nam JM, Bissell MJ (2014) Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Investig 124(1):367–384. doi:10.1172/JCI63146

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Granchi C, Minutolo F (2012) Anticancer agents that counteract tumor glycolysis. ChemMedChem 7(8):1318–1350. doi:10.1002/cmdc.201200176

    PubMed Central  CAS  PubMed  Google Scholar 

  14. Jang M, Kim SS, Lee J (2013) Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 45:e45. doi:10.1038/emm.2013.85

    PubMed Central  PubMed  Google Scholar 

  15. Banaszak K, Mechin I, Obmolova G, Oldham M, Chang SH, Ruiz T, Radermacher M, Kopperschlager G, Rypniewski W (2011) The crystal structures of eukaryotic phosphofructokinases from baker’s yeast and rabbit skeletal muscle. J Mol Biol 407(2):284–297. doi:10.1016/j.jmb.2011.01.019

    CAS  PubMed  Google Scholar 

  16. Hasawi NA, Khandari MA, Luqmani YA (2014) Phosphofructokinase: a mediator of glycolytic flux in cancer progression. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2014.05.007

    PubMed  Google Scholar 

  17. Prabhakar NR, Semenza GL (2012) Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92(3):967–1003. doi:10.1152/physrev.00030.2011

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Liang J, Mills GB (2013) AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73(10):2929–2935. doi:10.1158/0008-5472.CAN-12-3876

    PubMed Central  CAS  PubMed  Google Scholar 

  19. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899. doi:10.1038/nrc1478

    CAS  PubMed  Google Scholar 

  20. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202(3):654–662. doi:10.1002/jcp.20166

    CAS  PubMed  Google Scholar 

  21. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(34):4777–4786. doi:10.1038/sj.onc.1209603

    PubMed Central  CAS  PubMed  Google Scholar 

  22. Pedersen PL (2007) Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39(3):211–222. doi:10.1007/s10863-007-9094-x

    CAS  PubMed  Google Scholar 

  23. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg Effect” and a pivotal target for effective therapy. Semin Cancer Biol 19(1):17–24. doi:10.1016/j.semcancer.2008.11.006

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF (2012) Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget 3(9):940–953

    PubMed Central  PubMed  Google Scholar 

  25. Li Z, Yang P, Li Z (2014) The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta 1846(2):285–296. doi:10.1016/j.bbcan.2014.07.008

    CAS  PubMed  Google Scholar 

  26. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG (2013) PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155(2):397–409. doi:10.1016/j.cell.2013.09.025

    CAS  PubMed  Google Scholar 

  27. Gao X, Wang H, Yang JJ, Liu X, Liu ZR (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45(5):598–609. doi:10.1016/j.molcel.2012.01.001

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480(7375):118–122. doi:10.1038/nature10598

    PubMed Central  CAS  PubMed  Google Scholar 

  29. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150(4):685–696. doi:10.1016/j.cell.2012.07.018

    PubMed Central  CAS  PubMed  Google Scholar 

  30. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y, Lu Z (2014) PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell 53(1):75–87. doi:10.1016/j.molcel.2013.11.001

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Kwon OH, Kang TW, Kim JH, Kim M, Noh SM, Song KS, Yoo HS, Kim WH, Xie Z, Pocalyko D, Kim SY, Kim YS (2012) Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun 423(1):38–44. doi:10.1016/j.bbrc.2012.05.063

    CAS  PubMed  Google Scholar 

  32. Lee J, Kim HK, Han YM, Kim J (2008) Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 40(5):1043–1054. doi:10.1016/j.biocel.2007.11.009

    CAS  PubMed  Google Scholar 

  33. Luo W, Hu H, Chang R, Zhong J, Knabel M, O’Meally R, Cole RN, Pandey A, Semenza GL (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145(5):732–744. doi:10.1016/j.cell.2011.03.054

    PubMed Central  CAS  PubMed  Google Scholar 

  34. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593–602. doi:10.1016/S0092-8674(00)81902-9

    CAS  PubMed  Google Scholar 

  35. Chen Q, Ames BN (1994) Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 91(10):4130–4134

    PubMed Central  CAS  PubMed  Google Scholar 

  36. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J (2003) Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5(8):741–747. doi:10.1038/ncb1024

    CAS  PubMed  Google Scholar 

  37. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M (2005) Tumour biology: senescence in premalignant tumours. Nature 436(7051):642. doi:10.1038/436642a

    CAS  PubMed  Google Scholar 

  38. Kondoh H, Lleonart ME, Nakashima Y, Yokode M, Tanaka M, Bernard D, Gil J, Beach D (2007) A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal 9(3):293–299. doi:10.1089/ars.2007.9.ft-14

    CAS  PubMed  Google Scholar 

  39. Okuda J, Niizuma S, Shioi T, Kato T, Inuzuka Y, Kawashima T, Tamaki Y, Kawamoto A, Tanada Y, Iwanaga Y, Narazaki M, Matsuda T, Adachi S, Soga T, Takemura G, Kondoh H, Kita T, Kimura T (2013) Persistent overexpression of phosphoglycerate mutase, a glycolytic enzyme, modifies energy metabolism and reduces stress resistance of heart in mice. PLoS One 8(8):e72173. doi:10.1371/journal.pone.0072173

    PubMed Central  CAS  PubMed  Google Scholar 

  40. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O (2011) Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem 80:825–858. doi:10.1146/annurev-biochem-060608-102511

    PubMed Central  CAS  PubMed  Google Scholar 

  41. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3(2):177–182. doi:10.1038/nm0297-177

    CAS  PubMed  Google Scholar 

  42. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92(12):5510–5514

    PubMed Central  CAS  PubMed  Google Scholar 

  43. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, Keith B (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20(5):557–570. doi:10.1101/gad.1399906

    PubMed Central  CAS  PubMed  Google Scholar 

  44. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281(22):15215–15226. doi:10.1074/jbc.M511408200

    CAS  PubMed  Google Scholar 

  45. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63(19):6130–6134

    CAS  PubMed  Google Scholar 

  46. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149–162. doi:10.1101/gad.12.2.149

    PubMed Central  CAS  PubMed  Google Scholar 

  47. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3(3):177–185. doi:10.1016/j.cmet.2006.02.002

    PubMed  Google Scholar 

  48. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3(3):187–197. doi:10.1016/j.cmet.2006.01.012

    CAS  PubMed  Google Scholar 

  49. Kennedy KM, Dewhirst MW (2010) Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 6(1):127–148. doi:10.2217/fon.09.145

    PubMed Central  CAS  PubMed  Google Scholar 

  50. Maynard MA, Ohh M (2007) The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci CMLS 64(16):2170–2180. doi:10.1007/s00018-007-7082-2

    CAS  Google Scholar 

  51. Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325–337. doi:10.1038/nrc3038

    CAS  PubMed  Google Scholar 

  52. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23(9):1949–1956. doi:10.1038/sj.emboj.7600196

    PubMed Central  CAS  PubMed  Google Scholar 

  53. Gariboldi MB, Ravizza R, Monti E (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80(4):455–462. doi:10.1016/j.bcp.2010.05.011

    CAS  PubMed  Google Scholar 

  54. Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T, Gorlach A (2007) Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 18(12):4691–4697. doi:10.1091/mbc.E07-04-0391

    PubMed Central  CAS  PubMed  Google Scholar 

  55. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G, Flamme I (2003) Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278(9):7520–7530. doi:10.1074/jbc.M211298200

    CAS  PubMed  Google Scholar 

  56. Le Bras A, Lionneton F, Mattot V, Lelievre E, Caetano B, Spruyt N, Soncin F (2007) HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 26(53):7480–7489. doi:10.1038/sj.onc.1210566

    PubMed  Google Scholar 

  57. Bingham C, Hattersley AT (2004) Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant Off Publication Eur Dial Transpl Assoc Eur Renal Assoc 19(11):2703–2708. doi:10.1093/ndt/gfh348

    CAS  Google Scholar 

  58. Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, Baba T, Hamanishi J, Abiko K, Kosaka K, Murphy SK, Mori S, Konishi I (2013) Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog. doi:10.1002/mc.22072

    PubMed  Google Scholar 

  59. Itamochi H, Kigawa J, Terakawa N (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99(4):653–658. doi:10.1111/j.1349-7006.2008.00747.x

    CAS  PubMed  Google Scholar 

  60. Baba T, Otake H, Sato T, Miyabayashi K, Shishido Y, Wang CY, Shima Y, Kimura H, Yagi M, Ishihara Y, Hino S, Ogawa H, Nakao M, Yamazaki T, Kang D, Ohkawa Y, Suyama M, Chung BC, Morohashi K (2014) Glycolytic genes are targets of the nuclear receptor Ad4BP/SF-1. Nat Commun 5:3634. doi:10.1038/ncomms4634

    CAS  PubMed  Google Scholar 

  61. Discher DJ, Bishopric NH, Wu X, Peterson CA, Webster KA (1998) Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 273(40):26087–26093. doi:10.1074/jbc.273.40.26087

    CAS  PubMed  Google Scholar 

  62. Schafer D, Hamm-Kunzelmann B, Brand K (1997) Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1. FEBS Lett 417(3):325–328. doi:10.1016/S0014-5793(97)01314-8

    CAS  PubMed  Google Scholar 

  63. Panasyuk G, Espeillac C, Chauvin C, Pradelli LA, Horie Y, Suzuki A, Annicotte JS, Fajas L, Foretz M, Verdeguer F, Pontoglio M, Ferre P, Scoazec JY, Birnbaum MJ, Ricci JE, Pende M (2012) PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat Commun 3:672. doi:10.1038/ncomms1667

    PubMed Central  PubMed  Google Scholar 

  64. Singh PK, Mehla K, Hollingsworth MA, Johnson KR (2011) Regulation of Aerobic Glycolysis by microRNAs in Cancer. Mol Cell Pharmacol 3(3):125–134

    PubMed Central  CAS  PubMed  Google Scholar 

  65. Yang F, Zhang H, Mei Y, Wu M (2014) Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell 53(1):88–100. doi:10.1016/j.molcel.2013.11.004

    CAS  PubMed  Google Scholar 

  66. Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2(2):103–112. doi:10.1016/S1535-6108(02)00102-2

    CAS  PubMed  Google Scholar 

  67. Feng Z, Levine AJ (2010) The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 20(7):427–434. doi:10.1016/j.tcb.2010.03.004

    PubMed Central  CAS  PubMed  Google Scholar 

  68. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277(41):38205–38211. doi:10.1074/jbc.M203781200

    CAS  PubMed  Google Scholar 

  69. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39(2):171–183. doi:10.1016/j.molcel.2010.06.022

    PubMed Central  PubMed  Google Scholar 

  70. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE (2003) Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278(17):14599–14602. doi:10.1074/jbc.C300063200

    CAS  PubMed  Google Scholar 

  71. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64(11):3892–3899. doi:10.1158/0008-5472.CAN-03-2904

    CAS  PubMed  Google Scholar 

  72. Ro TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Borset M (2013) HGF and IGF-1 synergize with SDF-1alpha in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp Hematol 41(7):646–655. doi:10.1016/j.exphem.2013.03.002

    PubMed  Google Scholar 

  73. Sun J, Khalid S, Rozakis-Adcock M, Fantus IG, Jin T (2009) P-21-activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine. Oncogene 28(35):3132–3144. doi:10.1038/onc.2009.167

    CAS  PubMed  Google Scholar 

  74. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R (2009) PAK signaling in oncogenesis. Oncogene 28(28):2545–2555. doi:10.1038/onc.2009.119

    PubMed Central  CAS  PubMed  Google Scholar 

  75. Shalom-Barak T, Knaus UG (2002) A p21-activated kinase-controlled metabolic switch up-regulates phagocyte NADPH oxidase. J Biol Chem 277(43):40659–40665. doi:10.1074/jbc.M206650200

    CAS  PubMed  Google Scholar 

  76. Tunduguru R, Chiu TT, Ramalingam L, Elmendorf JS, Klip A, Thurmond DC (2014) Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells. Biochem Pharmacol. doi:10.1016/j.bcp.2014.08.033

    PubMed  Google Scholar 

  77. Cooper JA, Reiss NA, Schwartz RJ, Hunter T (1983) Three glycolytic enzymes are phosphorylated at tyrosine in cells transformed by Rous sarcoma virus. Nature 302(5905):218–223. doi:10.1038/302218a0

    CAS  PubMed  Google Scholar 

  78. Hitosugi T, Zhou L, Fan J, Elf S, Zhang L, Xie J, Wang Y, Gu TL, Aleckovic M, LeRoy G, Kang Y, Kang HB, Seo JH, Shan C, Jin P, Gong W, Lonial S, Arellano ML, Khoury HJ, Chen GZ, Shin DM, Khuri FR, Boggon TJ, Kang S, He C, Chen J (2013) Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun 4:1790. doi:10.1038/ncomms2759

    PubMed Central  PubMed  Google Scholar 

  79. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science Signal 2(97):ra73. doi:10.1126/scisignal.2000431

    Google Scholar 

  80. Yeung SJ, Pan J, Lee MH (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis—the seventh hallmark of cancer. Cell Mol Life Sci CMLS 65(24):3981–3999. doi:10.1007/s00018-008-8224-x

    CAS  Google Scholar 

  81. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94(13):6658–6663

    PubMed Central  CAS  PubMed  Google Scholar 

  82. Kawauchi K, Araki K, Tobiume K, Tanaka N (2008) p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10(5):611–618. doi:10.1038/ncb1724

    CAS  PubMed  Google Scholar 

  83. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275(29):21797–21800. doi:10.1074/jbc.C000023200

    CAS  PubMed  Google Scholar 

  84. Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O’Donnell KA, Dang CV (2004) Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 24(13):5923–5936. doi:10.1128/MCB.24.13.5923-5936.2004

    PubMed Central  CAS  PubMed  Google Scholar 

  85. David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463(7279):364–368. doi:10.1038/nature08697

    PubMed Central  CAS  PubMed  Google Scholar 

  86. Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR (2010) The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci USA 107(5):1894–1899. doi:10.1073/pnas.0914845107

    PubMed Central  CAS  PubMed  Google Scholar 

  87. Mathupala SP, Heese C, Pedersen PL (1997) Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272(36):22776–22780. doi:10.1074/jbc.272.36.22776

    CAS  PubMed  Google Scholar 

  88. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126(1):107–120. doi:10.1016/j.cell.2006.05.036

    CAS  PubMed  Google Scholar 

  89. Burns DM, Richter JD (2008) CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev 22(24):3449–3460. doi:10.1101/gad.1697808

    PubMed Central  CAS  PubMed  Google Scholar 

  90. Ruiz-Lozano P, Hixon ML, Wagner MW, Flores AI, Ikawa S, Baldwin AS Jr, Chien KR, Gualberto A (1999) p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression. Cell Growth Differ 10(5):295–306

    CAS  PubMed  Google Scholar 

  91. Mikawa T, Maruyama T, Okamoto K, Nakagama H, Lleonart ME, Tsusaka T, Hori K, Murakami I, Izumi T, Takaori-Kondo A, Yokode M, Peters G, Beach D, Kondoh H (2014) Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. J Cell Biol 204(5):729–745. doi:10.1083/jcb.201306149

    PubMed Central  CAS  PubMed  Google Scholar 

  92. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479. doi:10.1146/annurev.biochem.67.1.425

    CAS  PubMed  Google Scholar 

  93. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296–299. doi:10.1038/387296a0

    CAS  PubMed  Google Scholar 

  94. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387(6630):299–303. doi:10.1038/387299a0

    CAS  PubMed  Google Scholar 

  95. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53(10 Suppl):2231–2234

    CAS  PubMed  Google Scholar 

  96. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53(12):2736–2739

    CAS  PubMed  Google Scholar 

  97. Brown DR, Thomas CA, Deb SP (1998) The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 17(9):2513–2525. doi:10.1093/emboj/17.9.2513

    PubMed Central  CAS  PubMed  Google Scholar 

  98. Manfredi JJ (2010) The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 24(15):1580–1589. doi:10.1101/gad.1941710

    PubMed Central  CAS  PubMed  Google Scholar 

  99. McCay CM, Crowell MF (1934) Prolonging the life span. Sci Mon 39(5):405–414

    Google Scholar 

  100. Canto C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20(2):98–105. doi:10.1097/MOL.0b013e328328d0a4

    PubMed Central  CAS  PubMed  Google Scholar 

  101. Yecies JL, Manning BD (2011) mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 89(3):221–228. doi:10.1007/s00109-011-0726-6

    CAS  PubMed  Google Scholar 

  102. Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene 27(Suppl 2):S43–S51. doi:10.1038/onc.2009.352

    PubMed Central  CAS  PubMed  Google Scholar 

  103. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Costoya JA, Senaris R (2013) AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res 73(8):2628–2638. doi:10.1158/0008-5472.CAN-12-0861

    CAS  PubMed  Google Scholar 

  104. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J, Asara J, McGraw TE, Kahn BB, Cantley LC (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 49(6):1167–1175. doi:10.1016/j.molcel.2013.01.035

    PubMed Central  CAS  PubMed  Google Scholar 

  105. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18(3):283–293. doi:10.1016/j.molcel.2005.03.027

    CAS  PubMed  Google Scholar 

  106. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17(1):113–124. doi:10.1016/j.cmet.2012.12.001

    PubMed Central  CAS  PubMed  Google Scholar 

  107. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403(6771):795–800. doi:10.1038/35001622

    CAS  PubMed  Google Scholar 

  108. Zwaans BM, Lombard DB (2014) Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis Models Mech 7(9):1023–1032. doi:10.1242/dmm.016287

    CAS  Google Scholar 

  109. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, Deng CX (2011) SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20(4):487–499. doi:10.1016/j.ccr.2011.09.004

    PubMed Central  CAS  PubMed  Google Scholar 

  110. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, Gius D (2010) SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17(1):41–52. doi:10.1016/j.ccr.2009.11.023

    PubMed Central  CAS  PubMed  Google Scholar 

  111. Jeong SM, Lee A, Lee J, Haigis MC (2014) SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J Biol Chem 289(7):4135–4144. doi:10.1074/jbc.M113.525949

    PubMed Central  CAS  PubMed  Google Scholar 

  112. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenson JK, MacDonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weissleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB, Mostoslavsky R (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151(6):1185–1199. doi:10.1016/j.cell.2012.10.047

    PubMed Central  CAS  PubMed  Google Scholar 

  113. Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, Imai S (2013) Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab 18(3):416–430. doi:10.1016/j.cmet.2013.07.013

    PubMed Central  CAS  PubMed  Google Scholar 

  114. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen HY (2012) The sirtuin SIRT6 regulates lifespan in male mice. Nature 483(7388):218–221. doi:10.1038/nature10815

    CAS  PubMed  Google Scholar 

  115. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL (2012) SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 19(6):2011–2019. doi:10.1245/s10434-011-2159-4

    PubMed  Google Scholar 

  116. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY (2009) Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 15(13):4453–4459. doi:10.1158/1078-0432.CCR-08-3329

    CAS  Google Scholar 

  117. Noguchi A, Kikuchi K, Zheng H, Takahashi H, Miyagi Y, Aoki I, Takano Y (2014) SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med. doi:10.1002/cam4.310

    PubMed Central  PubMed  Google Scholar 

  118. Yuan J, Minter-Dykhouse K, Lou Z (2009) A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 185(2):203–211. doi:10.1083/jcb.200809167

    PubMed Central  CAS  PubMed  Google Scholar 

  119. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 38(6):864–878. doi:10.1016/j.molcel.2010.05.023

    CAS  PubMed  Google Scholar 

  120. Zhong L, D’Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R (2010) The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140(2):280–293. doi:10.1016/j.cell.2009.12.041

    PubMed Central  CAS  PubMed  Google Scholar 

  121. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish CB, Pandolfi PP, Haigis MC (2011) SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 19(3):416–428. doi:10.1016/j.ccr.2011.02.014

    PubMed Central  CAS  PubMed  Google Scholar 

  122. Hubbi ME, Hu H, Kshitiz, Gilkes DM, Semenza GL (2013) Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J Biol Chem 288(29):20768–20775. doi:10.1074/jbc.M113.476903

    PubMed Central  CAS  PubMed  Google Scholar 

  123. Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy AJ, Valenzuela DM, Luo H, Kapahi P, Krauss R, Mostoslavsky R, Yancopoulos GD, Alt FW, Chua KF, Chen D (2013) SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep 5(3):654–665. doi:10.1016/j.celrep.2013.10.007

    PubMed Central  CAS  PubMed  Google Scholar 

  124. Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, Qian DZ (2011) HDAC4 protein regulates HIF1alpha protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem 286(44):38095–38102. doi:10.1074/jbc.M111.257055

    PubMed Central  CAS  PubMed  Google Scholar 

  125. Zhao D, Zou SW, Liu Y, Zhou X, Mo Y, Wang P, Xu YH, Dong B, Xiong Y, Lei QY, Guan KL (2013) Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell 23(4):464–476. doi:10.1016/j.ccr.2013.02.005

    CAS  PubMed  Google Scholar 

  126. Tsusaka T, Guo T, Yagura T, Inoue T, Yokode M, Inagaki N, Kondoh H (2014) Deacetylation of phosphoglycerate mutase in its distinct central region by SIRT2 down-regulates its enzymatic activity. Genes Cells Devoted Mol Cell Mech 19(10):766–777. doi:10.1111/gtc.12176

    CAS  Google Scholar 

  127. Xu Y, Li F, Lv L, Li T, Zhou X, Deng CX, Guan KL, Lei QY, Xiong Y (2014) Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res 74(13):3630–3642. doi:10.1158/0008-5472.CAN-13-3615

    PubMed Central  CAS  PubMed  Google Scholar 

  128. Hallows WC, Yu W, Denu JM (2012) Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J Biol Chem 287(6):3850–3858. doi:10.1074/jbc.M111.317404

    PubMed Central  CAS  PubMed  Google Scholar 

  129. Li T, Liu M, Feng X, Wang Z, Das I, Xu Y, Zhou X, Sun Y, Guan KL, Xiong Y, Lei QY (2014) Glyceraldehyde-3-phosphate dehydrogenase is activated by lysine 254 acetylation in response to glucose signal. J Biol Chem 289(6):3775–3785. doi:10.1074/jbc.M113.531640

    PubMed Central  CAS  PubMed  Google Scholar 

  130. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, Lei QY (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42(6):719–730. doi:10.1016/j.molcel.2011.04.025

    CAS  PubMed  Google Scholar 

  131. Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, Lei QY, Xiong Y (2013) Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell 52(3):340–352. doi:10.1016/j.molcel.2013.09.004

    PubMed Central  CAS  PubMed  Google Scholar 

  132. Kaelin WG Jr, Maher ER (1998) The VHL tumour-suppressor gene paradigm. Trends Genet TIG 14(10):423–426. doi:10.1016/S0168-9525(98)01558-3

    CAS  Google Scholar 

  133. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97(19):10430–10435. doi:10.1073/pnas.190332597

    PubMed Central  CAS  PubMed  Google Scholar 

  134. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275. doi:10.1038/20459

    CAS  PubMed  Google Scholar 

  135. Chan DA, Sutphin PD, Yen SE, Giaccia AJ (2005) Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25(15):6415–6426. doi:10.1128/MCB.25.15.6415-6426.2005

    PubMed Central  CAS  PubMed  Google Scholar 

  136. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F (2004) JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118(6):781–794. doi:10.1016/j.cell.2004.08.025

    CAS  PubMed  Google Scholar 

  137. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, Olivier AK, Spitz DR, Gius D (2010) Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 40(6):893–904. doi:10.1016/j.molcel.2010.12.013

    PubMed Central  CAS  PubMed  Google Scholar 

  138. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8(2):143–153. doi:10.1016/j.ccr.2005.06.017

    CAS  PubMed  Google Scholar 

  139. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7(1):77–85. doi:10.1016/j.ccr.2004.11.022

    CAS  PubMed  Google Scholar 

  140. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277(26):23111–23115. doi:10.1074/jbc.M202487200

    CAS  PubMed  Google Scholar 

  141. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1):17–30. doi:10.1016/j.ccr.2010.12.014

    PubMed Central  CAS  PubMed  Google Scholar 

  142. Keller KE, Tan IS, Lee YS (2012) SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 338(6110):1069–1072. doi:10.1126/science.1224409

    PubMed Central  CAS  PubMed  Google Scholar 

  143. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329(5998):1492–1499. doi:10.1126/science.1188015

    CAS  PubMed  Google Scholar 

  144. Musi N, Goodyear LJ (2003) AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand 178(4):337–345. doi:10.1046/j.1365-201X.2003.01168.x

    CAS  PubMed  Google Scholar 

  145. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diabet Care 33(7):1674–1685. doi:10.2337/dc10-0666

    Google Scholar 

  146. Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS (2011) Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One 6(11):e28068. doi:10.1371/journal.pone.0028068

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan

    Takumi Mikawa, Nobuya Inagaki & Hiroshi Kondoh

  2. Department of Pathology, Hospital Vall de’Hebron, Paseo Vall d’Hebron 119-129, 08035, Barcelona, Spain

    Matilde E. LLeonart

  3. Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan

    Akifumi Takaori-Kondo

  4. Department of Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan

    Akifumi Takaori-Kondo

  5. Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, 606-8507, Japan

    Masayuki Yokode

  6. Geriatric Unit, Kyoto University Hospital, Kyoto, 606-8507, Japan

    Hiroshi Kondoh

Authors
  1. Takumi Mikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matilde E. LLeonart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akifumi Takaori-Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuya Inagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masayuki Yokode
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Kondoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Kondoh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mikawa, T., LLeonart, M.E., Takaori-Kondo, A. et al. Dysregulated glycolysis as an oncogenic event. Cell. Mol. Life Sci. 72, 1881–1892 (2015). https://doi.org/10.1007/s00018-015-1840-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-015-1840-3

Keywords

Search

Navigation